Apmonia Therapeutics
PrivateLast Round
Series A
Feb 3, 2026
Total Funding Raised
$17.4M
Company Overview
Apmonia Therapeutics operates in Healthcare & Life Sciences and is based in Reims. Its latest recorded funding round was a Series A round in February 2026.
Apmonia Therapeutics is a biotechnology company that develops peptide-based immunotherapy strategies for the treatment of solid tumors by targeting the tumor microenvironment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apmonia Therapeutics Comparables
Compare Apmonia Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PEP-Therapy | 85% | |
| Sapience Therapeutics | 81% | |
| Vigeo Therapeutics | 81% |
For institutional investors. Book with your work email.
Apmonia Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 3, 2026 | ||||
| Grant | Jul 16, 2024 | ||||
| Grant | Apr 23, 2024 | ||||
| VC Round | Feb 10, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Apmonia Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| France 2030 | Grant |
| European Innovation Council Fund | Grant |
| Angels Santé | Series A, VC Round |
| Finovam Gestion | Series A, VC Round |
| Capital Grand Est | Series A, VC Round |
| Business Angels Marne Ardennes | Seed |
| Capital Cell | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Monthly visitors increased 83% MoM.
- Feb 21, 2026
Grew 27% QoQ from 15 to 19 employees.
For institutional investors. Book with your work email.
Apmonia Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Apmonia Therapeutics's valuation, stock price, and market status.
Is Apmonia Therapeutics a public or private company?
Apmonia Therapeutics is a private company.
What is the current stock price of Apmonia Therapeutics?
Apmonia Therapeutics is a private company, so its shares have no public market price. Caplight tracks Apmonia Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Apmonia Therapeutics worth (valuation)?
Valuation information for Apmonia Therapeutics is not publicly available.
Can I buy Apmonia Therapeutics stock?
Apmonia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Apmonia Therapeutics's last funding round?
Apmonia Therapeutics's most recent funding round was Series A on February 3, 2026.
Who are the main investors in Apmonia Therapeutics?
Key investors in Apmonia Therapeutics include France 2030, European Innovation Council Fund, Angels Santé, Finovam Gestion, Capital Grand Est.
Will Apmonia Therapeutics IPO soon?
No public IPO plans have been announced for Apmonia Therapeutics.
How can I track Apmonia Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Apmonia Therapeutics's shares on secondary markets.